Health Pharma Research

Novo Nordisk’s test drug outperforms rival Lilly’s in diabetic patients

HQ Team September 21, 2026: Danish drugmaker Novo Nordisk’s investigational drug, CagriSema, has achieved an estimated average weight loss of 12.4% in diabetic.

Read More
Drugs Health Pharma

Novo Nordisk’s obesity drug CagriSema cuts weight by 23%

HQ Team June 22, 2025: Novo Nordisk A/S’s data from a clinical trial of a weight-loss medicine, treating overweight and obese adult participants,.

Read More